
Delaware lawmakers to vote on corporate law overhaul in face of criticism
WILMINGTON, DEL., March 20 (Reuters) - Delaware lawmakers are expected to vote to overhaul the state's corporate law on Thursday to protect its business-friendly reputation, but opponents have called the bill a giveaway to billionaires.
The bill makes it hard for investors to sue over certain transactions involving controlling shareholders, such as buying a controlling shareholder's business, if the deal follows certain steps. It also applies to deals with board members and executives, but will not impact existing rules for a takeover of the company by the controlling shareholder.
Attorneys who represent shareholders have dubbed the proposal "the billionaire's bill" and have launched a public campaign against it, politicizing the normally sleepy annual process of tweaking the corporate code.
The bill, known as SB 21, comes as a trickle of companies leaving Delaware raised concerns of a "DExit" stampede out of one of the country's smallest and least populated states. While other states are trying to attract incorporations, Delaware still remains home to most large public companies and related fees generate 20% of its budget revenue.
Several companies, mostly with controlling shareholders, have said they might or will leave Delaware, including Dropbox (DBX.O), opens new tab, Meta Platforms, opens new tab (META.O), opens new tab, TripAdvisor (TRIP.O), opens new tab and President Donald Trump's media company.
The state's senate approved the bill last week and Governor Matt Meyer has said he will sign it.
Amy Simmerman, a corporate lawyer in Wilmington, told the Delaware House Judiciary Committee, which approved the bill on Wednesday, that she has 15 significant corporate clients that she declined to identify which were considering leaving the state. "This is serious," she told lawmakers. "I don't think it's just bluffing."
Under the proposed bill, if a deal is approved by a board committee that has a majority of independent directors or by a vote by public shareholders, investors cannot challenge it in court. Currently, litigation can only be avoided if both steps are used and the committee must be entirely made up of independent directors.
The bill also makes it harder to challenge whether a director is independent. It defines "controlling shareholder" and limits records available to shareholders who want to investigate a deal for conflicts.
At Wednesday's committee hearing, lawmakers focused largely on the risk of companies leaving Delaware. Witnesses included corporate lawyers, law professors and a former judge on the state's Court of Chancery, its business court, and mostly spoke in support of the bill.
Public comment was dominated by opposition from attorneys who represent shareholders, who said they were excluded from the drafting process. They described the changes as radical, rushed and corrupt.
Joel Fleming, who represents shareholders, told lawmakers the bill was a result of lobbying by Meta Platforms and would protect its CEO and controlling shareholder Mark Zuckerberg from potential liability that shareholders are currently investigating. CNBC published documents on Wednesday it obtained from an open records request showing that the governor met with Meta officials in the weeks leading up the bill be proposed.
"Those claims may now be dead," Fleming told the lawmakers. "This is appalling."
The governor's spokeswoman Mila Myles said the governor met with Meta representatives to discuss corporate law but said the company did not lobby for the bill. She said the governor has been "meeting with everyone" so the state remains a global leader.
Meta declined to comment.
Corporate leaders have expressed frustration in recent years over court rulings that upset certain expectations about the state's law. Elon Musk fueled the debate last year by urging companies to follow Tesla (TSLA.O), opens new tab and leave the state after a Delaware judge rescinded his $56 billion pay package as CEO of the electric car maker.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Telegraph
24 minutes ago
- Telegraph
WhatsApp breaks co-founder's promise of ‘no ads'
Meta has unveiled plans to introduce adverts on WhatsApp, breaking a promise by the messaging app's co-founder never to do so. In a major update announced on Monday, WhatsApp said it will roll out paid advertising to its 3bn monthly users over the next few months. The move is in direct violation of the 'no ads, no games, no gimmicks' pledge made by Meta following its $19bn (£14bn) acquisition of WhatsApp in 2014. Jan Koum, WhatsApp's co-founder and chief executive at the time, had the mantra written on a note taped to his desk. In a 2012 blog post entitled 'Why we don't sell ads', he wrote: 'Remember, when advertising is involved you the user are the product.' The decision to abandon this promise risks fuelling concerns that the app is becoming more of a social media platform instead of a messaging service. It also comes after Meta began rolling out its own artificial intelligence (AI) function within WhatsApp, allowing users to interact with a chatbot similar to ChatGPT. Meta AI also offers AI-powered search suggestions.


Telegraph
24 minutes ago
- Telegraph
Trump to force NHS to pay for wonder drugs
NHS patients have been given new hope of accessing wonder drugs previously blocked in Britain as Donald Trump pressures the health service to spend more with US suppliers. Ministers are understood to be reviewing the value-for-money rules that govern which drugs the NHS can buy, amid demands from the Trump administration for the UK to be more welcoming to US pharmaceutical companies. Under the trade agreement signed between the two nations earlier this year, the Government agreed to 'endeavour to improve the overall environment for pharmaceutical companies operating in the UK'. Earlier this week, The Telegraph revealed that this could result in the NHS paying more for US drugs to see off criticism of the differences in medicine prices between the two nations. However, it is understood that discussions include not only paying more for treatments already supplied on the NHS but also making it easier for US drug giants to sell their most cutting-edge treatments to the health service. It follows a wave of high-profile rejections of so-called 'wonder' drugs in recent years. The National Institute of Health and Care Excellence (Nice), which approves new NHS drugs for purchase, has blocked treatments including one which stopped the progression of Alzheimer's disease and another that doubled the life expectancy for terminal breast cancer patients. Nice has rejected them based on assessments of how long they would extend a patient's lifespan and improve quality of life. To qualify under Nice rules a new treatment must deliver one extra year of perfect health, or longer for less perfect health, for no more than £30,000. This figure has not increased in line with inflation since 1999. If it had, it would be just over £53,000. Nice has maintained that, to get approval for use on the NHS, medicines 'must not only provide benefits to patients but also represent a good use of NHS resources and taxpayers' money'. However, critics say a failure to raise the threshold in-line with inflation meant life-changing drugs were being blocked. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said: 'There is growing evidence that it is becoming harder to bring new medicines to NHS patients. Increasingly, some new medicines may not be launched in the UK at all.' Companies including US giant Eli Lilly have said the regulator must rethink how 'value-for-money' is assessed. On Monday, a spokesman for the company said: 'The UK has historically focused on medicines as a cost to the NHS rather than evaluating their social and economic value.' Ministers are understood to be listening to demands from the industry for Nice to shake up its formula, with medicines such as AstraZeneca's breast cancer treatment Enhertu likely to be resubmitted for approval for NHS use if the formula is updated. Nice and AstraZeneca previously failed to reach an agreement over a price for the drug, which costs an estimated £118,000 per course of treatment. The NHS typically gets discounts, although the level is commercially sensitive. The Nice formula is being discussed after President Trump took a personal interest in the NHS issue. In trade documents between the US and UK, it said the NHS would review drug pricing to take into account the 'concerns of the president'. US officials are particularly concerned by an arrangement that sees companies pay revenue back to the NHS if costs rise faster than expected. Drug companies paid £3bn back to the NHS last year. In April, Wes Streeting, the Health Secretary, said he was proud that the UK had kept prices of medicines low. However, he admitted that the UK had become too focused on cost rather than the benefits in some cases. Mr Streeting said: 'We've moved from quite rightly trying to drive a good bargain on the price of drugs and treatment to a position where sometimes people view medicine spend as a dead weight cost'.


The Independent
33 minutes ago
- The Independent
This airline was named No.1 in North America in the ‘Oscars of Aviation' ... and Donald Trump isn't going to like it
Donald Trump may not like hearing this, but Air Canada has been rated the best airline in North America for 2025. That's according to the Skytrax World Airline Awards — known as the 'Oscars of Aviation' — which has placed what Trump might call the '51st state's' namesake carrier in first place in its North America ranking, ahead of Delta Air Lines in second and Porter Airlines in third. The rest of the top five rounds out with United Airlines (fourth) and JetBlue (fifth). Air Canada has also had success in the World's Best Business Class Airline Lounge for Dining category, with the Toronto Pearson Signature Suite claiming gold. And Canada triumphs in the Best Leisure Airlines category, with Montreal-based Air Transat coming top for the third consecutive year, ahead of the UK's Tui Airways (second) and Turkey-based SunExpress (third). "Receiving this award for the seventh time and third year in a row is an honour for everyone at Air Transat," said Pamela Lloyd-Bergeron, Air Transat Director In-Flight Service. "It reflects our dedication to delivering excellent service and memorable journeys for our passengers." Globally, however, North America fares badly, with Air Canada only managing 19th in the global ranking, which is topped by Qatar Airways for the ninth time. The rest of the global top five comprises Singapore Airlines (second), Cathay Pacific (third), Emirates (fourth) and ANA All Nippon Airways (fifth). Turkish Airlines is named the Best Airline in Europe, as well as winning the award for World's Best Business Class Onboard Catering. Qatar Airways also wins the Best Business Class category, with Singapore Airlines claiming the top podium spot for the First Class ranking. Edward Plaisted, CEO of Skytrax, said: "We welcomed back a large number of previous winners and were also delighted to see new faces and airlines represented here today. North America's top 10 airlines for 2025 Air Canada Delta Air Lines Porter Airlines United Airlines JetBlue Airways Alaska Airlines Air Transat Breeze Airways WestJet Allegiant Air The world's top 20 airlines for 2025 Qatar Airways Singapore Airlines Cathay Pacific Emirates ANA All Nippon Airways Turkish Airlines Korean Air Air France Japan Airlines Hainan Airlines Swiss Int'l Air Lines EVA Air British Airways Qantas Airways Lufthansa Virgin Atlantic Saudi Arabian Airlines STARLUX Airlines Air Canada Iberia As is indicated by so many former winning airlines being awarded again, quality consistency is clearly well recognised by customers when they vote for these airlines." The awards were given out at a gala ceremony held today at the Paris Air Show, with the results produced by a global customer satisfaction study.